Compare Vertex Pharmaceuticals Incorporated (VRTX) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vertex Pharmaceuticals Incorporated vs Zscaler Inc — how do they compare? Vertex Pharmaceuticals Incorporated trades at $508.15 (market cap $127.55B), while Zscaler Inc trades at $225.99 (market cap $35.35B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 3.6× Zscaler Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Zscaler Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Vertex Pharmaceuticals Incorporated for 120 Days and Zscaler Inc for 41 Days on average.
| VRTX | ZS | |
|---|---|---|
Market Cap | $127.55B | $35.35B |
Volume | 1,487,944 | 3,726,203 |
Sector | Health | Technology |
52-Week High | $557.96 | $336.27 |
52-Week Low | $407.37 | $118.05 |
Typical Hold Time | 120 Days | 41 Days |
Enterprise Value | $121.68B | $33.73B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Vertex Pharmaceuticals (VRTX) trades at $505.64, up 0.63% with mixed technical signals showing bearish moving averages but neutral oscillators. The company maintains strong fundamentals with $12B revenue, 35% net margin, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Earnings show volatility with Q1 beat but Q2 miss against expectations.
Outlook remains positive with 84% analyst buy ratings and $573.50 consensus target offering 13% upside. Key risks include clinical trial outcomes, competitive pressures, and reliance on cystic fibrosis portfolio. The stock presents growth potential through pipeline expansion but faces sector volatility and execution challenges.
Zscaler (ZS) trades at $213.55, up 0.61% with strong technical momentum as the stock approaches resistance near $216. The company demonstrates robust revenue growth, increasing from $1.1B in 2022 to $2.67B in 2025, while narrowing net losses from -$390M to -$41M. Recent earnings beats and 79.6% analyst buy ratings support positive sentiment, though negative profitability metrics and high valuation multiples present challenges.
The outlook remains cautiously optimistic with a $222.83 consensus price target suggesting 4.3% upside potential. Key opportunities include accelerating AI security demand and expanding platform adoption, while risks involve continued profitability challenges, executive transitions, and competitive pressures in the cybersecurity sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
